Biocon has entered into a definitive agreement with Mylan for an exclusive strategic collaboration for the global development and commercialisation of generic versions of its three insulin analog products.
Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon’s Glargine (the generic version of Sanofi’s Lantus), Lispro (the generic version of Eli Lilly’s Humalog) and Aspart (the generic version of Novo Nordisk’s NovoLog).
Mylan and Biocon will share development, capital and certain other costs to bring the products to market. Mylan will have exclusive commercialisation rights in the US, Canada, Australia, New Zealand, the European Union and the European Free Trade Association countries through a profit share arrangement with Biocon. Mylan will have co-exclusive commercialisation rights with Biocon in certain other markets around the world.
Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, “Mylan is a natural preferred partner for our portfolio of generic insulin analogs and this collaboration further strengthens our existing successful partnership. We are excited to team up with Mylan to be able to cost effectively address the disease and economic burden that diabetes poses to global health. We are confident that together we can build a strong global presence in generic Insulin analogs and thereby provide access to affordable therapy options to physicians, healthcare providers and diabetes patients worldwide.”
Heather Bresch, Chief Executive Officer, Mylan commented, “This collaboration builds off of our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products. This collaboration further expands and diversifies our pipeline of complex, difficult-to-manufacture products with strong future growth potential. Importantly, we believe we have the opportunity to be one of the first generic entrants in developed markets into the rapidly growing diabetes area, helping to address unmet needs and reduce the economic burden to those battling the disease and to the global healthcare system.”
Rajiv Malik, President, Mylan added, “Biocon has served as a trusted development partner for the past three years and we are excited about this expanded relationship. Our thorough review of the development work completed by Biocon to date on these products gives us great confidence in the company’s capabilities in this area and in the quality and value of this programme. Our confidence in the potential of this programme is supported by our proven ability to drive value from our partnership with Biocon and we believe Mylan is uniquely positioned to work with Biocon to bring these products to market.”
EP News Bureau – Mumbai
